Opus Genetics 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

George Magrath

최고 경영자

US$3.1m

총 보상

CEO 급여 비율	3.0%
CEO 임기	less than a year
CEO 소유권	0.6%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

George Magrath 의 보수는 Opus Genetics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$27m
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$3m	US$96k	-US$10m

보상 대 시장: George 의 총 보상 ($USD 3.15M )은 German 시장( $USD 471.14K ).

보상과 수익: George 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

George Magrath (40 yo)

less than a year

테뉴어

US$3,146,518

보상

Mr. George Magrath, MD, MBA, Ms. serves as CEO & Director of Opus Genetics, Inc. (formerly known as Ocuphire Pharma, Inc.) since November 1, 2023. He was an Analyst at Edison Investment Research Limited si...

리더십 팀

이름	위치	테뉴어	보상	소유권
George Magrath	CEO & Director	less than a year	US$3.15m	0.61% € 187.9k
Bernhard Hoffmann	Senior Vice President of Corporate Development & Secretary	no data	US$789.92k	0.34% € 104.9k
Jay Pepose	Chief Medical Advisor & Director	no data	US$662.10k	0.23% € 70.4k
Amy Zaremba Rabourn	Senior Vice President of Finance	no data	US$789.92k	0.025% € 7.5k
Nirav Suresh Jhaveri	Chief Financial Officer	less than a year	데이터 없음	0.48% € 146.1k
Joseph Schachle	Chief Operating Officer	less than a year	데이터 없음	0.0064% € 1.9k
Ashwath Jayagopal	Chief Scientific & Development Officer	less than a year	데이터 없음	0.25% € 76.5k
Bindu Manne	Head of Market Development & Commercialization	2.8yrs	데이터 없음	데이터 없음
Erik Sims	Director & Corporate Controller	no data	데이터 없음	데이터 없음

1.0yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 관리: R3X1 의 관리팀은 경험 (평균 재직 기간 1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
George Magrath	CEO & Director	less than a year	US$3.15m	0.61% € 187.9k
Jay Pepose	Chief Medical Advisor & Director	3.4yrs	US$662.10k	0.23% € 70.4k
James S. Manuso	Independent Director	4yrs	US$154.81k	0.29% € 88.5k
David Boyer	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Richard Rodgers	Independent Director	4yrs	US$1.35m	0.52% € 158.8k
Jeffrey Heier	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Peter Kaiser	Member of Medical Advisory Board	4.8yrs	데이터 없음	데이터 없음
Susan Benton	Independent Director	4yrs	US$135.34k	0.31% € 96.3k
Cameron Gallagher	Independent Chairman	4yrs	US$174.62k	0.11% € 35.0k
Sean Ainsworth	Lead Independent Director	4yrs	US$149.56k	0.15% € 46.0k
David Lally	Member of Medical Advisory Board	2.9yrs	데이터 없음	데이터 없음
David Brown	Member of Medical Advisory Board	2.9yrs	데이터 없음	데이터 없음

4.0yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: R3X1 의 이사회는 경험(평균 재직 기간 4 년)으로 간주됩니다.

Opus Genetics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer

Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023

Insufficient new directors

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Recent updates

Third quarter 2024 earnings released: US$0.29 loss per share (vs US$0.26 profit in 3Q 2023)

Ocuphire Pharma, Inc. (NasdaqCM:OCUP) acquired Opus Genetics, Inc. for $25.8 million.

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$0.24 loss in 2Q 2023)

New major risk - Share price stability

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.28 loss in 1Q 2023)

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study

New minor risk - Profitability

Full year 2023 earnings released: US$0.46 loss per share (vs US$0.90 profit in FY 2022)

Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer

Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy

Ocuphire Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Investor sentiment improves as stock rises 15%

Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023

Insufficient new directors

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Ocuphire Pharma, Inc. Announces Chief Executive Officer Changes

Investor sentiment deteriorates as stock falls 15%

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

New minor risk - Shareholder dilution

Ocuphire Pharma, Inc. to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit

Investor sentiment improves as stock rises 16%

Ocuphire Pharma, Inc. Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association's Annual Conference

Investor sentiment deteriorates as stock falls 19%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 24%

Ocuphire Pharma, Inc. Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol Eye Drops for Reversal of Mydriasis

Ocuphire Pharma, Inc. Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

Ocuphire Pharma Announces First Patient Enrolled in Vega-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

Ocuphire Pharma, Inc. Announces Submission of New Drug Application to FDA for Nyxol Eye Drops for Reversal of Mydriasis

Forecast to breakeven in 2022

High number of new and inexperienced directors

Forecast to breakeven in 2022

Forecast to breakeven in 2024

Ocuphire Pharma, Inc. Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol and Strategic Partnership with American Society of Ophthalmic Administrators

Ocuphire Expands Medical Advisory Board with Seven New Kols and Strengthens Leadership Team

Ocuphire Pharma, Inc. Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy

Ocuphire Pharma, Inc. to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics At Annual Macula Society Meeting

Ocuphire Pharma, Inc., Annual General Meeting, Jun 13, 2022

Ocuphire Pharma, Inc. Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances

Forecast to breakeven in 2024

High number of new directors

No longer forecast to breakeven

Ocuphire Pharma, Inc. Appoints Jay Pepose as Chief Medical Advisor

Ocuphire Pharma, Inc. Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis

Ocuphire Pharma, Inc. Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis

Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations

Ocuphire Pharma, Inc. Provides Update on its APX3330 and Nyxol Clinical Programs

Ocuphire Pharma, Inc. Initiates Enrollment of Nyxol Mira-4 Pediatric Study in Rm Per Agreed Initial Pediatric Study Plan with FDA

Forecast to breakeven in 2024

Ocuphire Pharma, Inc. Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis

Board Member recently bought €51k worth of stock

Insider recently bought €77k worth of stock

Ocuphire Pharma, Inc. Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease

Ocuphire Pharma, Inc.'s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints

Ocuphire Pharma, Inc. Completes Enrollment in VEGA-1 Phase 2 Clinical Trial Investigating Nyxol in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia

Ocuphire Pharma, Inc. Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint

Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol

Ocuphire Pharma, Inc. Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology

Ocuphire Pharma, Inc. Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis

Ocuphire Pharma, Inc. Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances

Ocuphire Pharma, Inc. Announces First Patient Enrolled in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis

Ocuphire Pharma, Inc. Appoints My Rabourn as the Vice President of Finance and Principal Accounting Officer

Ocuphire Pharma, Inc. Announces Milestones for Patents on Both of its Lead Drug Candidates Nyxol and APX3330